Drug Search Results
More Filters [+]

Ospemifene

Alternative Names: ospemifene, osphena
Latest Update: 2024-06-21
Latest Update Note: News Article

Product Description

Ospemifene is a selective estrogen receptor modulator (SERM) approved by the FDA for moderate to severe dyspareunia and vaginal dryness due to postmenopausal VVA. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/31526199/)

Mechanisms of Action: ER Modulator

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Approved

Approved Countries: Austria | Bangladesh | Belgium | Canada | Croatia | Czech | Estonia | European Medicines Agency | Finland | Germany | Hungary | Iceland | Ireland | Italy | Latvia | Lithuania | Poland | Portugal | Slovakia | Spain | Sweden | United Kingdom | United States

Approved Indications: Dyspareunia | Menopause

Known Adverse Events: Spasm | Hyperhidrosis | Vaginal Discharge

Company: None
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Ospemifene

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Recent News Events